Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Oct 1, 2015

166_ip_2015-10-01_ebde1d3b-0777-41dc-8ef0-1d63f7c1df23.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Health Care Worldwide

Crédit Suisse – Global Credit Products ConferenceOctober 1, 2015 - Barcelona

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Agenda

  • Company Overview
  • Business Segments
  • Fresenius Medical Care
  • Fresenius Kabi
  • Fresenius Helios
  • Fresenius Vamed
  • Financial Overview
  • Financing Facilities and Debt Structure
  • Summary and Outlook

Company Overview

Fresenius Group: A Global Leader in Health Care Products and Services

  • Sales €25.9 bn, net income1 €2.1 bn LTM June 2015
  • Strong and well-diversified portfolio
  • Global presence in approx. 100 countries
  • Long-term opportunities in growing, non-cyclical markets
  • Leading market positions

1 – Net income incl. attributable to non-controlling interest, before one-time items

Fresenius Group: Strong and Balanced Health Care Portfolio

Market Cap.5 €22.6 bn

  • 1 Before special items
  • 2 Based on market cap of FSE as of September 21, 2015
  • 3 Based on consolidated market capitalization of FSE and FME as of as of September 21, 2015 and consolidated net debt as of June 30, 2015
  • 4 Held by Fresenius ProServe GmbH, a wholly owned subsidiary of FSE
  • 5 Based on market cap of FME as of September 21, 2015

Fresenius Group: Financial Results

Sales 5-year CAGR: 10%

EBIT1 5-year CAGR: 8%

Net Income1,2 5-year CAGR: 11%

2 – Incl. attributable to non-controlling interest

20153 – 2011 sales were adjusted by -€161m according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 7

Fresenius Group: Organic Growth 1999 – 2015

Fresenius Group:

Sustainable Organic Sales Growth in all Business Segments

Fresenius Medical Care

Fresenius Kabi

Fresenius Helios

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 9

Fresenius Vamed

Fresenius Group: Financial Results

/
H
1
1
5		 /
H
1
1
4
S
l
a
e
s		 h
G
t
r
o
w
c
c
G
h
l
t
t
t
o
a
a
a
e
s
r
w
c
u
r		 €
1
3
4
2
9
m
,
1
3
%
2
%
5		 €
1
0
7
3
3
m
,
1
E
B
I
T		 h
G
t
r
o
w
c
c
h
l
G
t
t
t
r
o
w
a
c
u
a
r
a
e
s		 €
8
2
2
1
m
,
1
5
%
3
0
%		 €
0
3
1
4
m
,
1,
2
N
i
t
e
n
c
o
m
e		 h
G
t
o
c
c
r
w
h
l
G
t
t
t
r
o
w
a
c
u
a
r
a
e
s		 €
0
1
5
1
m
,
1
8
%
3
3
%		 €
8
8
7
m

1 – Before special items

2 – Incl. attributable to non-controlling interest

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 10

Fresenius Group: Financial Results by Business Segment

/
2
0
H
1
1
5		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
l
S
a
e
s
h
G
t
o
r
w		 \$
8
1
5
9
m
,
1
0
%		 €
2
9
3
2
m
,
1
9
%		 €
2
7
7
4
m
,
1
0
%		 €
6
3
4
m
1
6
%
1
E
B
I
T
h
G
t
r
o
w		 \$
1
0
5
1
m
,
5
%		 €
5
7
1
m
3
9
%		 €
3
0
7
m
2
3
%		 €
1
6
m
7
%

1 – Before special items

Business Segments

Fresenius Medical Care: Global Market Leader in Dialysis

  • World leader in dialysis products and services treating 289,610 patients in 3,421 clinics worldwide1
  • Provide highest standard of patient care
  • Vertical integration
  • High quality products & services
  • Complete therapy offerings
  • Leader in growing market
  • Dialysis market growing 4% cc and estimated to reach around \$100 bn by 2020
  • Patient growth driven by age, life style and mortality reduction

~6% global patient growth p.a. ~3.8 million patients by 2020 expected

Fresenius Medical Care:Market Leader in All Regions1

h
N
t
A
o
r
m		 i
e
r
c
a
Pr
i
de
ov
r		 Pa
ie
t
ts
n		 Co
ie
tr
un
s
2
0
1
7
7,
7		 2
1
7
6,
2
0
0		 1
1
6,
0
5
0		 1
1
4,
8
0
0		 1
1
2,
2
5
0		 1
7,
4
3
0		 1
L
i
A
t
a
n
m		 i
e
r
c
a
i
de
Pr
ov
r		 ie
Pa
t
ts
n		 Co
ie
tr
un
s
3
2,
3
2
0		 8
8,
9
9
0		 2
0
0
4,
4		 3
2,
3
7
0		 1
9
3
0		 1
E
M
u
r
o
p
e
,		 i
d
d
l
E
e
a		 A
f
i
t,
s
r
c
a
Pr
i
de
ov
r		 Pa
ie
t
ts
n		 Co
ie
tr
un
s
5
3,
5
5
0		 2
5
2
1,
3
0
0		 1
5
1
8,
8
0
0		 1
1
3,
9
0
0		 1
8
9
0
0
6,		 1
O
h
t		 3,
5
9
0
e
r		 4
7 2,
0
6
6
%		 3
A
i
P
i
f
s
a
a
c		 i
c
i
de
Pr
ov
r		 ie
Pa
t
ts
n		 Co
ie
tr
un
s
2
6,
0
2
0		 1
2
5,
1
0
0		 1
4,
0
0
0		 1
3,
8
8
0		 5
1,
8
3
0		 5
3
4
0		 1

1 – Company data and estimates, as of June 30, 2015

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 14

Fresenius Medical Care: Key Figures H1/2015

€
\$
i
l
l
i
i
l
l
i
m
o
n
m
o
n		 /
Q
/
H
1
1
2
2
0
0
1
1
5
3		 /
Q
/
H
1
1
2
0
2
1
0
4
1
2		 G
h
G
t
h
t
r
o
r
o
w
w
l
S
l
T
t
o
a
a
e
s		 8
1
5
9
,		 7
3
9
8
,		 1
%
1
0
+
E
B
I
T
D
A		 1
4
0
8
,		 1
3
3
7
,		 %
5
+
E
B
I
T
D
A
i
m
a
r
g
n		 1
7
3
%		 1
8
1
%
E
B
I
T		 1
0
5
1
,		 1
0
0
1
,		 %
5
+
E
B
I
T
i
m
a
r
g
n		 2
9
%
1		 3
%
1
5
2
N
i
t
e
n
c
o
m
e		 4
5
0		 4
3
9		 3
%
+

1 – 8% organic growth, 9% acquisitions, -1% divestitures, -6% currency effects

2 – Net Income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care: Cash Flow H1/2015

\$
i
l
l
i
m
o
n		 /
H
1
2
0
1
5		 /
H
1
2
0
1
4
O
i
C
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 8
3
2		 5
6
2
C
O
i
h
F
l
M
i
t
p
e
r
a
n
g
a
s
o
w
a
r
g
n		 1
0
2
%		 7
6
%
C
(
)
t
a
p
e
x
n
e		 4
1
1
-		 4
1
5
-
F
C
h
F
l
r
e
e
a
s
o
w
(
b
f
i
i
i
d
d
i
i
d
d
)
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 4
2
1		 1
4
7
C
h
l
i
F
F
M
r
e
e
a
s
o
w
a
r
g
n		 %
5
2		 %
2
0
C
h
l
F
F
r
e
e
a
s
o
w
(
f
d
)
i
i
i
i
t
t
t
t
a
e
a
c
q
s
o
n
s
a
n
n
e
s
m
e
n
s
r
u
v		 3
5
5		 2
8
5
-

Fresenius Medical Care:Leverage Ratio and Ratings

Fresenius Kabi: A Worldwide Leading Hospital Supplier

    • Comprehensive product portfolio for critically and chronically ill patients
  • -IV Drugs
  • -Clinical Nutrition
  • -Infusion Therapy
  • -Medical Devices / Transfusion Technology
  • -Global addressable market: >€29 bn
  • -Leading market positions
    • Focus on organic growth driven by geographic product rollout and robust product pipeline
    • Aim to expand the business through selective acquisitions

LTM June 2015 Sales by Region

Fresenius Kabi: Strong Growth Track Record & High Profitability

Fresenius Kabi: Key Figures H1/2015

i
l
l
i
€
m
o
n		 /
H
1
2
0
1
5		 /
H
1
2
0
1
4		 G
h
t
r
o
w
S
l
a
e
s		 2
9
3
2
,		 2
4
6
6
,		 1
9
%
1
+
I.
V
D
g
s
r
u
-
l
l
C
i
i
N
i
i
t
t
n
c
a
o
n
u
r
-
f
h
I
i
T
n
u
s
o
n
e
r
a
p
y
-
d
l
/
M
i
D
i
e
c
a
e
v
c
e
s
-
f
i
h
l
T
T
n
o
n
e
n
o
o
g
r
a
s
u
s
c
y		 1,
1
9
1
7
7
2
6
8
4
0
1
5		 8
6
8
6
6
2
6
4
7
6
0
4		 3
7
%
+
1
7
%
+
2
%
-
9
%
+
2
E
B
I
T
D
A
E
B
I
T
D
A
i
m
a
r
g
n		 6
9
1
2
3
6
%		 5
1
3
2
0
8
%		 %
3
5
+
2
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 5
7
1
9
%
1
5		 4
1
1
%
1
6
7		 3
9
%
+
3
N
i
t
e
n
c
o
m
e		 3
0
9		 2
1
7		 2
%
4
+

1 – 8% organic growth, 1% acquisitions, -1% divestitures, 11% currency effects

2 – Before special items

3 – Net income attributable to shareholders of Fresenius Kabi AG; before special items

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 20

Fresenius Helios: Leading Hospital Operator in Germany

    • German Acute Care Hospital Market: ~€87 bn1, thereof 18% privatized
    • 6% share in German Acute Care Hospital Market
    • High-quality medical care, e.g., mortality rate for heart failure and pneumonia lower than German average (-30%), quality management system, transparency of medical outcomes
    • Strong track record in hospital operations and acquisitions: targeting 12 − 15% EBIT margin within 6 years per individual clinic location
    • Negligible bad debt ratio due to comprehensive population insurance coverage

Largest Network with 111 Hospitals

1 – German Federal Statistical Office 2014; total costs, gross of the German hospitals less academic research and teaching

Fresenius Helios: Strong Growth Track Record & Increased Profitability

Fresenius Helios: Key Figures H1/2015

€
i
l
l
i
m
o
n		 /
H
2
0
1
1
5		 /
H
2
0
1
1
4		 G
h
t
r
o
w
S
l
a
e
s		 2
7
7
4
,		 2
2
5
1
,		 1
0
%
1
+
2
E
B
I
T
D
A		 3
9
9		 3
4
4		 %
1
6
+
E
B
I
T
D
A
i
m
a
r
g
n		 1
4
4
%		 1
3
6
%
2
E
B
I
T		 3
0
7		 2
5
0		 2
3
%
+
E
B
I
T
i
m
a
r
g
n		 %
1
1
1		 9
9
%
3
N
i
t
e
n
c
o
m
e		 2
2
6		 1
7
9		 2
6
%
+

1 – 3% organic growth, 8% acquisitions, -1% divestitures

2 – Before special items

3 – Net income attributable to shareholders of HELIOS Kliniken GmbH; before special items

Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services

    • Specialized in project development building hospital infrastructure and providing hospital services (technical services and operational management)
  • Track record:

  • 710 health care projects in 77 countries successfully completed

  • Services provided to 510 hospitals and 130,000 beds globally
  • Continuous demand for hospital infrastructure and operating efficiency; key markets Europe, Asia-Pacific, Africa

Financial Overview

Fresenius Group: Demonstrated Strong Sales and EBITDA Growth

Fresenius Group: Key Figures H1/2015

€
i
l
l
i
m
o
n		 /
H
1
2
0
1
5		 /
H
1
2
0
1
4		 C
h
a
n
g
e
l
t
a
c
u
a
t
r
a
e
s		 C
h
a
n
g
e
t
t
c
o
n
s
a
n
t
r
a
e
s
S
l
a
e
s		 1
3
4
2
9
,		 1
0
7
3
3
,		 %
2
5
+		 1
%
1
3
+
2
E
B
I
T
D
A		 2
3
6
4
,		 1
8
5
4
,		 %
2
8
+		 %
1
3
+
2
E
B
I
T		 1
8
2
2
,		 1
4
0
3
,		 3
0
%
+		 1
5
%
+
I
t
t,
t
n
e
e
n
e
r
s		 3
3
0
-		 2
8
3
-		 %
1
7
-		 %
4
-
2
E
B
T		 1
4
9
2
,		 1
1
2
0
,		 %
3
3
+		 %
1
8
+
2
T
a
e
s
x		 4
4
1
-		 3
3
2
-		 3
3
%
-		 1
6
%
-
3,
4
N
i
t
e
n
c
o
m
e		 1
0
5
1
,		 8
8
7		 %
3
3
+		 8
%
1
+
E
l
m
p
o
y
e
e
s		 2
2
0
3
3
9
,		 2
0
9
9
3
3
,
  • 1 7% organic growth, 7% acquisitions, -1% divestitures
  • 2 Before special items
  • 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
  • 4 Incl. attributable to non-controlling interest

Fresenius Group: Cash Flow Development LTM

€
i
l
l
i
m
o
n		 O
p
e
r
a
L
T
M
H
1
/
1
5		 i
C
F
t
n
g
L
T
M
M
in
a
rg		 C
a
p
e
x
L
T
M
H
1
/
1
5		 (
)
t
n
e
L
T
M
H
1
/
1
5		 F
C
r
e
e
a
L
T
M
H
1
/
1
5		 1
h
F
l
s
o
w
L
T
M
M
in
a
rg
7
8
0		 1
3
9
%		 3
5
4
-		 6
3
%
-		 4
2
6		 7
6
%
5
8
4		 1
0
6
%		 2
6
1
-		 4
7
%
-		 3
2
3		 3
5
9
%
9 0
8
%		 2
1
-		 1
1
%
-		 3
-		 0
3
%
-
Co
/
te
rp
or
a
O
he
t
r		 2
4
-		 n
a		 1
1
-		 n
a		 3
5
-		 n
a
l.
C
F
M
ex
c		 1
3
4
9
,		 2
%
1
1
7		 6
3
8
-		 %
5
2
-		 7
1
1		 2
%
6
5
3
1
7
7
,		 2
9
%
1		 8
7
5
-		 6
%
5
-		 9
9
7		 3
%
7
Gr
ou
p		 3
0
8
6
,		 1
1
9
%		 1
3
9
6
-
,		 5
4
%
-		 1
6
9
0
,		 6
5
%
%
f s
Ma
in
in
rg
o
=

1 – Before acquisitions and dividends 3 – Understated: 6.8% excluding €53 million of capex commitments from acquisitions

2 – Margin incl. FMC dividend

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 28

Fresenius Group: Proven Track Record of Deleveraging

1 – Pro forma acquisitions; before special items

2 – At annual average exchange rates for both net debt and EBITDA; without major acquisitions; before special items

Fresenius Group: Debt and Interest Ratios

  • 1 Pro forma including Fresenius Medical Care acquisitions; excluding two HELIOS hospitals
  • 2 Before integration costs, disposal gains (two HELIOS hospitals) and costs for Fresenius Kabi efficiency program
  • 3 Before integration costs and disposal gains (two HELIOS hospitals; Rhön stake)
  • 4 Pro forma including acquired Rhön hospitals and Fresenius Medical Care acquisitions; excluding two HELIOS hospitals
  • 5 At annual average exchange rates for both net debt and EBITDA; without major acquisitions; before special items

Financing Facilities and Debt Structure

Fresenius Group: Current Debt and Cash Flow Structure - June 30, 2015

  • 1 External debt as of June 30, 2015
  • 2 Incl. Fresenius Finance B.V. and other financing subsidiaries

  • 3 Controlling stake

  • 4 As held by Fresenius ProServe GmbH, a wholly owned subsidiary of Fresenius SE & Co. KGaA, which provides the guarantees

  • 5 Incl. subsidiaries

Fresenius Group: Capitalization - June 30, 2015 & Pro Forma1

Q
2-
2
0
1
5		 Se
p		 d
j
d
fo
te
a
us
r
te
be
Is
m
r
su
an
ce
\$
€
i
l
l
io
m
n		 5
i
l
l
io
m
n		 €
i
l
l
io
m
n		 5
\$
i
l
l
io
m
n		 f to
%
o
l c
ta
ap		 E
A L
B
I
T
D
T
M
x
S
2
0
3
Cr
d
F
E
1
i
t
Ag
t:
Te
Lo
A
e
re
em
en
rm
an		 8
8
1,
5		 2,
0
9
7		 8
8
1,
5		 2,
0
9
7		 2.
8
%
d
F
S
E
2
0
1
3
Cr
i
t
Ag
t:
Te
Lo
B
e
re
em
en
rm
an		 4
3
9		 4
9
1		 4
3
9		 4
9
1		 0.
7
%
Se
io
No
te
n
r
s		 3,
1
8
7		 3,
5
6
6		 2,
4
6
5		 2,
7
5
8		 3.
7
%
Se
io
Ne
No
te
w
n
r
s		 2
6
8		 3
0
0		 %
0.
4
Co
i
b
le
Bo
ds
t
nv
er
n		 4
6
4		 5
1
9		 4
6
4		 5
1
9		 0.
7
%
Eu
No
te
ro
s		 9
1
7		 1,
0
2
6		 9
1
7		 1,
0
2
6		 1.
%
4
Co
l
ia
Pa
m
m
er
c
p
er		 3
0
1		 1
4
5		 8
5
4		 6
3
5		 0.
9
%
he
de
b
O
t
t,
g
ro
ss
r		 8
3
1		 4
2
6		 8
3
1		 4
2
6		 0.
6
%
(
),
To
l
De
b
F
S
E
l.
F
M
C
ta
t
ex
c
g
ro
ss		 7,
3
7
6		 8,
2
5
3		 7,
3
7
6		 8,
2
5
3		 1
1.
2
%
Ca
h
(
l.
F
M
C
)
s
ex
c		 3
9
7		 4
4
4		 3
9
7		 4
4
4		 0.
6
%
(
),
To
l
de
b
F
S
E
l.
F
M
C
ta
t
t
ex
c
n
e		 6,
9
7
9		 7,
8
0
9		 6,
9
7
9		 7,
8
0
9		 %
1
0.
6
l
de
b
2
To
ta
F
M
C
t,
t
ne		 7,
7
6
5		 8,
6
8
8		 7,
7
6
5		 8,
6
8
8		 1
1.
8
%
To
l c
l
i
da
d
de
b
ta
te
t,
t
on
so
ne		 1
4,
7
4
4		 1
6,
4
9
7		 1
4,
7
4
4		 1
6,
4
9
7		 2
2.
4
%		 3
3.
2x
Ma
ke
i
l
iza
io
3
t c
ta
t
r
ap
n		 5
1,
2
9
6		 5
7,
7
0
8		 5
1,
2
9
6		 5
7,
7
0
8		 7
7.
6
%		 1
1.
1x
l c
i
l
iz
io
To
ta
ta
t
ap
a
n		 6
6,
0
4
0		 7
4,
2
0
5		 6
6,
0
4
0		 7
4,
2
0
5		 %
1
0
0.
0		 1
4.
3x
4
Gr
F
S
E
E
B
I
T
D
A
ou
p		 4,
6
0
5

1 - Pro Forma Senior Notes Issuance, US\$ 300 million, as of September 25, 2015

2 - Net of Cash and intercompany adjustments

3 - Based on market capitalization for FSE and FMC as of September 21, 2015

4 - Before special items

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 33 5 - Exchange rate as of June 30, 2015, except for market capitalization which uses exchange rate as of September 21, 2015

Fresenius Medical Care:Debt Maturity Profile - June 30, 2015 1

1 – Based on utilization of major financing instruments

Fresenius Group excl. FMC: Debt Maturity Profile1 - June 30, 2015 Pro Forma2

Senior NotesEuro Notes (Schuldscheindarlehen) Credit Agreement Equity-neutral convertible bonds Commercial Papers

1 – Based on utilization of major financing instruments

  • 2 Pro Forma Senior Notes Issuance, US\$ 300 million, as of September 25, 2015
  • 3 Further long-term refinancing planned

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 35

Fresenius Group: Debt Maturity Profile1 - June 30, 2015 Pro Forma2

1 – Based on utilization of major financing instruments

2 – Pro Forma Senior Notes Issuance, US\$ 300 million, as of September 25, 2015

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 36

Summary and Outlook

Fresenius Medical Care: Financial Outlook

2
0
1
5
E		 2
0
1
6
P
j
i
t
r
o
e
c
o
n
S
l
a
e
s		 5
7
%
-
1
0-
1
2
%
cc		 7
1
0
%
c
c
-
N
I
t
e
n
c
o
m
e		 0
%
5
-		 1
2
0
%
5
-
    • The 2015 outlook and the projections for 2016 are based on current exchange rates and include savings from the Global Efficiency Program
  • -Potential acquisitions are not included
    • The outlook is based on the execution and the operating cost investments within Care Coordination - in line with our 2020 strategy
    • Topline revenue alignment for 2016 since we expect some of the initiatives in Care Coordination operations to be delayed into the following years

Fresenius Group: Increased Outlook for Fresenius Kabi

O
l
d		 N
e
w
i
F
r
e
s
e
n
u
s
K
b
i
a		 l
h
S
t
i
a
e
s
g
o
r
w
o
g
n
r
a
c
h
E
B
I
T
t
t
t
g
r
o
w
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 4
%
7
%
–
%
%
1
1
1
4
–		 6
%
8
%
–
8
%
2
%
1
1
–
F
i
r
e
s
e
n
s
u
H
l
i
e
o
s		 S
l
h
t
i
a
e
s
g
r
o
w
o
g
a
n
c
r
l
h
S
t
d
t
a
e
s
g
o
r
w
r
e
p
o
r
e
E
B
I
T		 3
%
%
5
–
6
%
9
%
–
€
6
3
0
6
0
5
m
–
i
F
r
e
s
e
n
s
u
V
d
a
m
e		 l
h
S
t
i
a
e
s
g
o
r
w
o
g
n
r
a
c
h
E
B
I
T
t
g
r
o
w		 l
d
i
i
i
%
t
s
n
g
e
g
–
%
0
%
5
1
–

Fresenius Group: Increased Earnings Guidance

O
l
d		 N
e
w
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 7
%
1
0
%
‒		 8
%
1
0
%
‒
1
h
N
i
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 1
3
%
1
6
%
–		 1
8
%
2
1
%
–

1 - Net income attributable to shareholders of Fresenius SE & Co.KGaA; 2015 before integration costs for hospitals of Rhön-Klinikum AG (~€10 m before tax), before costs for efficiency program at Fresenius Kabi (~€100 m before tax) and disposal gains from the divestment of two HELIOS hospitals (€34 m before tax); 2014 before special items

Fresenius Group: Ideal Strategic Posture to Benefit from Major Healthcare Trends

Aging population and higher incidence of chronic diseases

World population aged 60+ will more than double by 2050 to >2 bn (OECD)

Increasing health care spending in emerging markets

Increasing health care coverage and per capita spending (e.g. India: \$157, China: \$480, vs. USA: \$8,895; WHO)

Continuing growth of generics

Approx. \$19 bn branded IV drug sales (base: 2013) go off-patent in the U.S. by 2023

Rise of private providers in health care services

Further privatization of German hospital market Global opportunity to provide dialysis services (e.g. China, India)

Fresenius Group: Attractive Mid-Term Growth Prospects Exceeding Target at Current FX Rates

Mid-Term Target as released early 2014: ~ €30 billion sales, €1.4 to €1.5 billion net income1 by 2017

2017 net income target will be reached 2 years ahead of schedule; new mid-term targets in February 2016

Strong and Balanced Health Care Portfolio

1 – Excl. attributable non-controlling interest

Crédit Suisse Global Credit Products Conference – October 1, 2015 © Copyright Page 42

Fresenius Group: Investment Highlights

Leading market positions

Diversified revenue base with four strong business segments

Global presence in growing, non-cyclical markets

Proven ability to integrate acquisitions

Clear track record of and commitment to de-leveraging

Strong financial performance and cash flow generation

Health Care Worldwide

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.